In the tumor, node, and metastasis classification, cTNM was used for clinical classification, pTNM was used for pathologic classification, and the prefix y was used as a pathological classification following nCRT. For example, ypTNM was used for staging after nCRT.
Thirtyseven patients diagnosed with rectal cancer who had received nCRT were included in the study; 56.8% of patients were males, while 43.2% were females.
nCRT probably increases the survival rate and local disease control in patients with rectal cancer.
Patients chose inclusion to the direct surgery or nCRT groups based on the current stage of their disease and after understanding the risks and benefits and without the influence of the surgeon.
Generally, protective diverting ileostomy was performed in an effort to protect low rectal anastomosis, taking into considerations the general health of the patient, nutritional status, diabetes, the distance of the anastomosis from the anal verge, and the use of nCRT. Starting approximately 3 to 4 weeks after surgery, patients received adjuvant chemotherapy for 6 months.
To assess the association between NCRTS and survival outcomes and evaluate whether the newly published or updated clinical trials can influence the results of our previous study, a comprehensive search of randomized clinical trials (RCTs) comparing NCRTS versus SA was carried out, and an up-to-date meta-analysis was performed in this study.
The inclusion and exclusion criteria in the current updated meta-analysis were the same as the criteria in the previous meta-analysis.[sup] The criteria for eligibility of the studies were as follows: (1) RCTs evaluating NCRTS versus SA; (2) articles that provided survival data between patients from the NCRTS and SA groups; (3) articles that described the cases and controls in the diagnosis and the sources; and (4) having risk ratio ( RR ) with 95% confidence interval ( CI ) or data that could be calculated.
The purpose of this retrospective analysis was to assess and evaluate OS, progression-free survival (PFS), and local relapse-free survival (LRFS) in patients undergoing NCRT and ACRT in LARC in current clinical setting.
The medical records of patients with clinical stage T3-T4N0 or N1-2 rectal cancer who received either NCRT or ACRT between 2007 and 2009 were retrospectively analyzed.
Data regarding potential factors were assembled from medical records, including patients' age and sex, preoperative levels of serum CRP and albumin, tumor location, size, stage according to the 7th edition of the Union for International Cancer Control (UICC) and TNM staging according to the American Joint Committee on Cancer (AJCC) , tumor differentiation, resection margin, presence of lymphatic invasion, date and kind of surgical procedure, and NCRT
Nevertheless, those data were derived from comparisons between rectal MAC and non-MAC treated with nCRT based on nonmatched cohorts.
Therefore, to examine the benefits of nCRT for the treatment of locally advanced rectal MAC, this propensity score-matched study was designed to compare surgical and oncological outcomes for rectal MAC treated with nCRT and surgery alone.